- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results
- EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
- EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
- EQS-NVR: MorphoSys AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
- EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- EQS-News: Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
More ▼
Key statistics
As of last trade MorphoSys AG (MORX:GER) traded at 66.15, -2.72% below its 52-week high of 68.00, set on Apr 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 66.10 |
---|---|
High | 66.30 |
Low | 65.70 |
Bid | 66.05 |
Offer | 66.15 |
Previous close | 66.20 |
Average volume | 246.00k |
---|---|
Shares outstanding | 37.72m |
Free float | 31.58m |
P/E (TTM) | -- |
Market cap | 2.50bn EUR |
EPS (TTM) | -12.54 EUR |
Data delayed at least 15 minutes, as of May 02 2024 11:43 BST.
More ▼